Related Experiment Video
Updated: Dec 26, 2025
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Eudragit RL100 Based Moxifloxacin Hydrochloride and Ketorolac Tromethamine Combination Nanoparticulate System for
1Department of Pharmaceutics (PG), Gourishankar Institute of Pharmaceutical Education & Research, Limb, Survey No.990, NH-4, Satara-4150415, MS, India.
Background:
Bacterial conjunctivitis is a serious ocular infection if left untreated. It is caused by several species of bacteria like Pseudomonas, Staphylococcus and Mycobacterium.
Objective:
The present investigation explores the development and characterization of moxifloxacin hydrochloride and ketorolac tromethamine combination loaded Eudragit RL 100 nanosuspension for ocular drug delivery in order to overcome the problems associated with conventional dosage forms.
Methods:
The nanosuspension prepared by nanoprecipitation technique showed successful entrapment of both water-soluble drugs in the polymer matrix indicated by their % entrapment efficiencies.
Results:
Formulations showed a mean particle size <200 nm with narrow size distribution and positive surface charge due to the presence of quaternary ammonium groups of Eudragit RL100. FTIR study revealed compatibility among the components, while a reduction in the crystallinity of formulation was observed in the PXRD study. The release of both the drugs was found to be sustained in nanosuspension as compared to commercial eyedrops. Ex vivo studies showed increased transcorneal permeation of drugs from nanosuspension, where approximately 2.5-fold and 2-fold increase in the permeation was observed for moxifloxacin hydrochloride and ketorolac tromethamine, respectively. The formulation was stable at 4°C and room temperature.
Conclusion:
Due to their sustained release, positive surface charge and higher transcorneal permeation, this will be a promising ocular drug delivery.
Insights
This study developed a novel nanosuspension for bacterial conjunctivitis treatment, improving drug delivery to the eye. The new formulation offers sustained drug release and enhanced eye penetration, promising better treatment outcomes.
Area of Science:
- Ophthalmology
- Pharmaceutics
- Nanotechnology
Background:
- Bacterial conjunctivitis is a significant ocular infection requiring prompt treatment.
- Common causative agents include Pseudomonas, Staphylococcus, and Mycobacterium species.
Purpose of the Study:
- To develop and characterize a novel Eudragit RL 100 nanosuspension for ocular delivery of moxifloxacin hydrochloride and ketorolac tromethamine.
- To overcome limitations associated with conventional ophthalmic dosage forms.
Main Methods:
- Nanosuspension preparation using the nanoprecipitation technique.
- Characterization of particle size, surface charge, drug entrapment, and component compatibility (FTIR, PXRD).
- In vitro drug release studies and ex vivo transcorneal permeation assays.
Main Results:
- Successful entrapment of both drugs within the Eudragit RL 100 polymer matrix.
- Nanosuspensions exhibited particle size <200 nm, narrow size distribution, and positive surface charge.
- Sustained drug release and significantly increased transcorneal permeation (2.5-fold for moxifloxacin HCl, 2-fold for ketorolac tromethamine) compared to commercial eyedrops.
Conclusions:
- The developed nanosuspension demonstrates sustained drug release, enhanced ocular permeation, and good stability.
- This formulation represents a promising advancement in ocular drug delivery for bacterial conjunctivitis.
More Related Videos
09:20Novel Photoacoustic Microscopy and Optical Coherence Tomography Dual-modality Chorioretinal Imaging in Living Rabbit Eyes
Published on: February 8, 2018
07:49Slow-release Drug Delivery through Elvax 40W to the Rat Retina: Implications for the Treatment of Chronic Conditions
Published on: September 17, 2014
